Episodic Ataxia Treatment Market Report 2024

The episodic ataxia treatment market size has grown strongly in recent years. It will grow from $10.41 billion in 2023 to $11.07 billion in 2024 at a compound annual growth rate (CAGR) of 6.3%. The historical growth can be credited to a deeper understanding of genetic causes, more funding for rare disease research, greater availability of specialized clinics, heightened awareness of personalized medicine, and increased participation in clinical trials.

The episodic ataxia treatment market size is expected to see strong growth in the next few years. It will grow to $14.29 billion in 2028 at a compound annual growth rate (CAGR) of 6.6%. Future growth is expected to be driven by improved access to genetic testing, a higher demand for genetic counseling services, a rise in the number of clinical trials, more patient registries, and greater investment in rare disease biobanks. Key trends anticipated in the forecast period include advancements in technology, personalized medicine, telemedicine, stem cell therapy, and telerehabilitation services.

The growing prevalence of neurological disorders is anticipated to drive the expansion of the episodic ataxia treatment market. Neurological disorders encompass diseases affecting the central and peripheral nervous systems, including the brain, spinal cord, cranial and peripheral nerves, autonomic nervous system, nerve roots, neuromuscular junction, and muscles. Factors such as an aging population, genetic predispositions, and infectious diseases contribute to the rising incidence of neurological disorders. Episodic ataxia treatment aims to address symptoms and enhance the management of conditions involving intermittent coordination and balance loss. For example, in April 2022, the European Brain Council, a Belgium-based non-profit organization, reported that Dementia (a progressive neurological disorder) impacted 10.5 million people in Europe in 2022, with projections indicating an increase to 18.7 million by 2050. Consequently, the rising prevalence of neurological disorders is fueling the episodic ataxia treatment market.

Leading companies in the episodic ataxia treatment market are prioritizing the development of innovative solutions, such as treatments for Friedreich's ataxia (FA), to improve patient outcomes and address the unmet needs of this rare neurological condition. Episodic ataxia (EA) is characterized by sporadic episodes of ataxia and a lack of voluntary muscle coordination, with episodes varying in duration, frequency, and severity. For instance, in February 2024, Biogen Inc., a US-based biotechnology company, announced the approval of SKYCLARYS (omaveloxolone) for treating Friedreich's ataxia (FA). Omaveloxolone targets the underlying mitochondrial dysfunction associated with FA, potentially altering disease progression rather than merely alleviating symptoms. The therapy functions as a potent transcriptional modulator, aiding in the restoration of mitochondrial function and cellular energy production.

In November 2022, Kriya Therapeutics Inc., a US-based biopharmaceutical company, acquired Redpin Therapeutics Inc. for an undisclosed amount. This acquisition aims to significantly bolster Kriya Therapeutics' neurology pipeline by incorporating Redpin’s innovative treatments for neurological disorders into its existing gene therapy portfolio. Redpin Therapeutics Inc. is a US-based company dedicated to developing treatments for various neurological and neurodegenerative disorders, including episodic ataxia.

Major companies operating in the episodic ataxia treatment market are Pfizer Inc., AbbVie Inc., Sanofi, Bristol-Myers Squibb Company, Novartis AG, Takeda Pharmaceutical Company Limited, Merck KGaA, Banner Health, Astellas Pharma Inc., Daiichi Sankyo Company Limited, UCB S.A., Ipsen, BioMarin Pharmaceutical Inc., Neurocrine Biosciences Inc., PTC Therapeutics Inc., Kissei Pharmaceutical Co. Ltd., Catalyst Pharmaceuticals Inc., Design Therapeutics Inc., Larimar Therapeutics Inc., Voyager Therapeutics Inc., Capsida Biotherapeutics Inc., Adverum Biotechnologies Inc., CRISPR Therapeutics AG.

North America was the largest region in the episodic ataxia treatment market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the episodic ataxia treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the episodic ataxia treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Treatment for episodic ataxia encompasses medical strategies aimed at managing and alleviating the symptoms of this rare neurological disorder, which features intermittent episodes of poor coordination, balance issues, and sometimes vertigo. The approach includes medications, therapies, and lifestyle changes designed to control symptoms and enhance the quality of life for those affected.

The main treatment categories for episodic ataxia include ataxia telangiectasia, episodic ataxia, spinocerebellar ataxia, and Friedreich’s ataxia. Ataxia telangiectasia is a rare genetic disorder impacting both the nervous and immune systems, leading to progressive movement difficulties, an elevated risk of cancer, and other health concerns. Treatments for this condition may involve medications such as levodopa, pramipexole, and venlafaxine, administered through various methods including oral and parenteral routes. Distribution channels for these treatments include direct tenders and retail sales, serving different end users through these channels.

The episodic ataxia treatment market research report is one of a series of new reports that provides episodic ataxia treatment market statistics, including episodic ataxia treatment industry global market size, regional shares, competitors with an episodic ataxia treatment market share, detailed episodic ataxia treatment market segments, market trends and opportunities, and any further data you may need to thrive in the episodic ataxia treatment industry. This episodic ataxia treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The episodic ataxia treatment market consists of revenues earned by entities by providing services such as genetic counseling, physical therapy, and occupational therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. The episodic ataxia treatment market also includes sales of antiepileptic drugs, beta-blockers, genetic testing kits, and wearable health monitors. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.